Abstract: The invention relates to the use of a very low dosage form of abscisic acid (ABA) or an in vivo hydrolysable conjugate thereof, preferably ABA-glucosyl ester (ABA-GE), for nutracentic/therapeutic use for controlling and/or preventing hyperglycaemia and weight gain in response to sugar intake with a reduction in insulin secret and an increase in muscle performance.

Abstract: The invention relates to the use of a very low dosage form of abscisic acid (ABA) or an in vivo hydrolysable conjugate thereof, preferably ABA-glucosyl ester (ABA-GE), for nutracentic/therapeutic use for controlling and/or preventing hyperglycaemia and weight gain in response to sugar intake with a reduction in insulin secret and an increase in muscle performance.

Abstract: A method comprising, receiving digital-electrical input symbols of a stream of input symbols, the input symbols corresponding to signal points of a symbol constellation. The method also comprises classifying the input symbols, wherein a first symbol class comprises input symbols corresponding to signal points that are variant to rotation of the symbol constellation, and, a second symbol class comprises input symbols corresponding to signal points that are invariant to rotation of the symbol constellation. The method also comprises applying selective differential coding only to those input symbols of the first symbol class.

Abstract: A method comprising, receiving digital-electrical input symbols of a stream of input symbols, the input symbols corresponding to signal points of a symbol constellation. The method also comprises classifying the input symbols, wherein a first symbol class comprises input symbols corresponding to signal points that are variant to rotation of the symbol constellation, and, a second symbol class comprises input symbols corresponding to signal points that are invariant to rotation of the symbol constellation. The method also comprises applying selective differential coding only to those input symbols of the first symbol class.

Abstract: Glutathione derivatives (GSH) of formula I are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus.

Abstract: The invention relates to novel adenyl dinucleotides which are isomers of the dinucleotide Ap2A, having formulae (I) and (II). The dinucleotides of the invention have antitumour activity, particularly against tumours of haematological origin, such as for example leukaemias and lymphomas. The invention further relates to the use of such dinucleotides as antitumour medicaments. Finally, the invention relates to an enzymatic method for preparing the dinucleotides of formulae (I) and (II) and to an enzymatic assay method for the dinucleotide of formula (I) which is based on its complete conversion to NAD+.

Abstract: The invention relates to a novel use of fluridone—compound known per se and used as an aquatic erbicide—in the medical field, in particular as an active compound for preparing a medicament having anti-inflammatory activity. Pharmaceutical compositions comprising fluridone as an active compound and pharmaceutically acceptable carriers and/or diluents are also disclosed. Finally, there is disclosed the pro-inflammatory activity of abscisic acid (ABA), a plant hormone which is also found in mammal serum and against which fluridone acts an inhibitor.

Abstract: The invention relates to a novel use of fluridone—compound known per se and used as an aquatic erbicide—in the medical field, in particular as an active compound for preparing a medicament having anti-inflammatory activity. Pharmaceutical compositions comprising fluridone as an active compound and pharmaceutically acceptable carriers and/or diluents are also disclosed. Finally, there is disclosed the pro-inflammatory activity of abscisic acid (ABA), a plant hormone which is also found in mammal serum and against which fluridone acts an inhibitor.

Abstract: The invention relates to novel adenyl dinucleotides which are isomers of the dinucleotide Ap2A, having formulae (I) and (II). The dinucleotides of the invention have antitumour activity, particularly against tumours of haematological origin, such as for example leukaemias and lymphomas. The invention further relates to the use of such dinucleotides as antitumour medicaments. Finally, the invention relates to an enzymatic method for preparing the dinucleotides of formulae (I) and (II) and to an enzymatic assay method for the dinucleotide of formula (I) which is based on its complete conversion to NAD+.

Abstract: Glutathione derivatives (GSH) of formula (I) are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus.

Abstract: A process and a plant to carry out the purification in the sea of effluents (waste waters), in which the submarine biopurification of the latter is envisaged, when discharged into the sea. The process and the plant of the invention favor the dilution, in the sea, and recycling of the organic substances contained in the sewage, carrying out the correct disposal of the effluent and the desired cut down of the bacterial load contained in it.

Abstract: A process and a plant to carry out the purification in the sea of effluents (waste waters), in which the submarine biopurification of the latter is envisaged, when discharged into the sea. The plant of the invention, carrying of the correct disposal of the effluent and the desired cut down of the bacterial load contained in it, consist of a submarine load bearing framework (1), equipped with legs (4) fixed to a ballast (3) and able to support a collection chamber (5) and a filtering chamber (6) above the pipe outlet (10) for the effluents.

Abstract: 5',5'-Pyrophosphates of non-naturally occurring nucleosides selected from thymine-3'-azido-2',3'-dideoxy-D-riboside, 5-fluorouracil-2'-deoxy-D-riboside, uracil-3'-azido-2',3'-dideoxy-D-riboside, guanine-2',3'-dideoxy-D-riboside, hypoxanthing-2',3'-dideoxy-D-riboside, cytosine-2',3'-dideoxy-D-riboside, and adenine-2',3'-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutical pharmaceutical compositions or as pro-drugs encapsulated into biological carriers, e.g., transformed erythrocytes, for targeting to specific cell population responsible of the development of the pathological disorders.

Abstract: 5,5'-Pyrophosphates of non-naturally occurring nucleosides selected from 1-(1-thyminyl)-3-azido-2, 3-dideoxy-D-riboside, 1(5-fluoro-1-uracilyl)-2, 3-dideoxy-D-riboside, 1-(1-uracilyl)-3-azido-2, 3-dideoxy-D-riboside, 1-(9-guaninyl)-2, 3-dideoxy-D-riboside, 1-(9-hypoxanthinyl)-2, 3-dideoxy-D-riboside, 1-(1-cytosinyl)-2, 3-dideoxy-D-riboside, and 1-(9-adeninyl)-2, 3-dideoxy-D-riboside, are described as well as their manufacture and use as therapeutic agents against tumors and retroviral infections including HIV infections. The compounds may be administered as the active ingredients of pharmaceutical compositions or as prodrugs encapsulated within biological carriers, e.g. transformed erythrocytes, for targeting to specific cell populations responsible for the development of the noted pathological disorders.